arrow
F

Felice Crocetto

university of naples federico ii
H指数:39
被引数:4,869

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Pharmacological TRPM8 blockade reprograms patient-derived intestinal fibroblasts and mitigates experimental fibrosis through modulation of myofibroblast activation

药理学TRPM8阻断通过调节肌成纤维细胞活化重编程患者来源的肠成纤维细胞并减轻实验性纤维化

2026-10-200
OAAI
FGFR-Altered Urothelial Carcinoma in the EV–Pembrolizumab Era: Rationale and Emerging Data for Upfront Triplet Strategies

FGFR突变型尿路上皮癌在EV–帕博利珠单抗时代的治疗策略:早期三联疗法的合理性与新兴数据

2026-10-070
OAAI
PHI for adverse pathology and PHI density for upgrading: two complementary predictors in localized prostate cancer

前列腺健康指数(PHI)用于不良病理学和PHI密度用于升级:局部前列腺癌中的两种互补预测因子

2026-09-230
OA
Retroperitoneal Renal Surgery with the Hugo™ RAS System: Feasibility, Setting and Perioperative Outcomes of the First Dedicated Series

腹膜后肾手术使用Hugo™ RAS系统:首个专用系列的临床可行性、设置和围手术期结果

2026-08-010
OA
The impact of relative dose intensity on pathological complete response in neoadjuvant chemotherapy of muscle-invasive urothelial cancer: a multicenter retrospective study

相对剂量强度对肌肉浸润性尿路上皮癌新辅助化疗中病理完全缓解的影响:一项多中心回顾性研究

2026-07-020
OAAI
PEACE: Development and Validation of a Brief Five-Item Sleep Quality Scale for Community and Primary Care

PEACE:适用于社区和初级保健的简短五项睡眠质量量表的研制与验证

2026-04-150
OA
BLOSSOM Dietary Habits and 1-Year Intravesical Recurrence in High-Risk Non-Muscle-Invasive Bladder Cancer Treated with BCG

BLOSSOM饮食习惯与接受BCG治疗的高风险非肌层浸润性膀胱癌患者1年内腔内复发

2026-02-270
OAAI
Survival Outcomes of BCG Only, BCG Plus EMDA-MMC or Upfront Radical Cystectomy in High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): A Multicentre, International, Collaborative Study from Tertiary Referral Institutions
Cancers
IF4.4
2026-02-030
OAAI
Male Infertility: A Comprehensive Review of Urological Causes and Contemporary Management

男性不育症:泌尿系统病因的全面综述与当代管理

2026-01-060
OAAI
The influence of immunocompromised status on recurrence and progression free survival among nonmuscle invasive bladder cancers (NMIBCs) undergoing transurethral resection of bladder tumor (TURBT) and adjuvant intravesical bacillus Calmette Guerin (BCG): Analysis of USA insurance claim data

免疫抑制状态对接受经尿道膀胱肿瘤切除术(TURBT)和辅助性膀胱内卡介苗(BCG)治疗的非肌层浸润性膀胱癌(NMIBCs)患者复发及无进展生存期的影响:美国医疗保险索赔数据分析

2025-11-010
OAAI
Contemporary Trends and Predictors of pT0 in Radical Cystectomy Specimens Among Non-Muscle and Muscle-Invasive Bladder Cancer Patients: A Propensity Score-Matched Analysis from a Single Tertiary Centre in the United Kingdom

当代趋势及非肌层浸润性和肌层浸润性膀胱癌患者根治性膀胱切除术标本中pT0的预测因素:一项来自英国一家三级中心基于倾向性评分匹配的分析

2025-09-270
OAAI
Development and Validation of the PREVES-HOR Questionnaire: A Patient-Reported Measure of Hormone Therapy-Related Quality of Life in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy

PREVES-HOR问卷的开发与验证:一种用于接受雄激素剥夺治疗的前列腺癌患者激素疗法相关生活质量的自评量表

2025-09-010
PRE
Emerging Biomarkers in Bladder Cancer: Translating Molecular Advances into Precision Oncology

膀胱癌中的新兴生物标志物:将分子进展转化为精准肿瘤学

2025-07-230
PRE
Evaluating Treatment Efficacy in Metastatic Hormone-sensitive Prostate Cancer Patients with Visceral Disease: A Systematic Review and Network Meta-analysis

评估内脏疾病患者中转移性激素敏感性前列腺癌的治疗效果:一项系统评价和网络Meta分析

2025-07-100
OAAI
Impact of timing of computed tomography staging and patient factors on the detection of ‘true’ cN+ bladder cancer

计算机断层扫描分期时间及患者因素对检测“真”cN+膀胱癌的影响

2025-07-090
OAAI